RS61362B1 - Farmaceutske formulacije loratadina za inkapsulaciju i njihove kombinacije - Google Patents

Farmaceutske formulacije loratadina za inkapsulaciju i njihove kombinacije

Info

Publication number
RS61362B1
RS61362B1 RS20210013A RSP20210013A RS61362B1 RS 61362 B1 RS61362 B1 RS 61362B1 RS 20210013 A RS20210013 A RS 20210013A RS P20210013 A RSP20210013 A RS P20210013A RS 61362 B1 RS61362 B1 RS 61362B1
Authority
RS
Serbia
Prior art keywords
loratadine
encapsulation
combinations
pharmaceutical formulations
formulations
Prior art date
Application number
RS20210013A
Other languages
English (en)
Inventor
Beth Okutan
Peter Draper
James Draper
Original Assignee
Catalent Ontario Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Ontario Ltd filed Critical Catalent Ontario Ltd
Publication of RS61362B1 publication Critical patent/RS61362B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20210013A 2010-01-19 2011-01-18 Farmaceutske formulacije loratadina za inkapsulaciju i njihove kombinacije RS61362B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2690490A CA2690490C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
PCT/CA2011/000052 WO2011088550A1 (en) 2010-01-19 2011-01-18 Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
EP11734280.8A EP2525827B1 (en) 2010-01-19 2011-01-18 Pharmaceutical formulations of loratadine for encapsulation and combinations thereof

Publications (1)

Publication Number Publication Date
RS61362B1 true RS61362B1 (sr) 2021-02-26

Family

ID=44303619

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210013A RS61362B1 (sr) 2010-01-19 2011-01-18 Farmaceutske formulacije loratadina za inkapsulaciju i njihove kombinacije

Country Status (17)

Country Link
US (1) US20120301544A1 (sr)
EP (2) EP3653204A1 (sr)
JP (1) JP5328992B2 (sr)
AU (1) AU2011207058B2 (sr)
CA (1) CA2690490C (sr)
CY (1) CY1123895T1 (sr)
DK (1) DK2525827T3 (sr)
ES (1) ES2843351T3 (sr)
HR (1) HRP20201923T1 (sr)
HU (1) HUE053412T2 (sr)
LT (1) LT2525827T (sr)
MX (1) MX344163B (sr)
PL (1) PL2525827T3 (sr)
PT (1) PT2525827T (sr)
RS (1) RS61362B1 (sr)
SI (1) SI2525827T1 (sr)
WO (1) WO2011088550A1 (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103784399B (zh) * 2014-03-05 2015-09-30 大连金石滩药业有限公司 氯雷他定液体组合物
CN103784446B (zh) * 2014-03-05 2016-01-06 大连金石滩药业有限公司 氯雷他定组合物
JP7065562B2 (ja) * 2015-09-04 2022-05-12 ロート製薬株式会社 医薬組成物
KR101746500B1 (ko) 2016-05-26 2017-06-14 (주)알피바이오 연질캡슐 제제용 로라타딘 조성물 및 이를 함유하는 연질캡슐
US11607384B2 (en) 2017-12-08 2023-03-21 Western University Of Health Sciences Lipid emulsified drug delivery systems for chemoprevention and treatment
MX2020012233A (es) 2018-05-16 2021-01-29 Bayer Healthcare Llc Formula de suspension de alta concentracion para medicamentos en capsula de gel blanda para resfriado y gripe.
CN112426404B (zh) * 2020-10-29 2023-02-28 太阳升(亳州)生物医药科技有限公司 用于制备富马酸卢帕他定口服液的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
AU570306B2 (en) 1984-02-15 1988-03-10 Schering Corporation 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts.
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US4910205A (en) 1988-05-02 1990-03-20 Schering Corporation Transdermal delivery of loratadine
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
ZA925581B (en) * 1991-07-26 1993-05-14 Smithkline Beecham Corp Pharmaceutical microemulsions.
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
CA2181241C (en) * 1994-01-24 2000-04-25 Dadi Jamshed Dhabhar Process for solubilizing difficultly soluble pharmaceutical actives
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
NZ284068A (en) * 1994-04-07 1998-06-26 Smithkline Beecham Plc Medicament comprising halofantrine free base
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
ATE274907T1 (de) 1998-06-30 2004-09-15 Pfizer Prod Inc Loratadin zur verwendung als antiarrhythmikum
US6221391B1 (en) * 1998-11-23 2001-04-24 Accucaps Industries Limited Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
ES2294197T3 (es) * 2001-12-21 2008-04-01 Supernus Pharmaceuticals, Inc. Formulacion de capsula oral con estabilidad fisica aumentada.
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
RU2007139819A (ru) * 2005-03-29 2009-05-10 МакНЕЙЛ-Пи-Пи-Си, ИНК. (US) Композиции с гидрофильными лекарствами в гидрофобной среде
US20110020440A1 (en) * 2007-11-19 2011-01-27 Cadila Pharmaceuticals Limited Stable solutions of sparingly soluble actives

Also Published As

Publication number Publication date
ES2843351T3 (es) 2021-07-16
EP3653204A1 (en) 2020-05-20
PT2525827T (pt) 2021-01-20
HRP20201923T1 (hr) 2021-02-05
DK2525827T3 (da) 2020-12-14
CY1123895T1 (el) 2022-05-27
EP2525827B1 (en) 2020-11-18
LT2525827T (lt) 2021-03-25
US20120301544A1 (en) 2012-11-29
SI2525827T1 (sl) 2021-02-26
CA2690490C (en) 2012-06-26
CA2690490A1 (en) 2011-07-19
WO2011088550A1 (en) 2011-07-28
AU2011207058B2 (en) 2015-04-23
JP2013517303A (ja) 2013-05-16
HUE053412T2 (hu) 2021-06-28
JP5328992B2 (ja) 2013-10-30
MX344163B (es) 2016-12-07
MX2012008301A (es) 2012-09-28
EP2525827A1 (en) 2012-11-28
PL2525827T3 (pl) 2021-05-04
AU2011207058A1 (en) 2012-09-06
EP2525827A4 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
EP2395975A4 (en) ORAL PHARMACEUTICAL COMPOSITION OF DUTASTERIDE
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
PL3178472T3 (pl) Doustne preparaty metylonaltreksonu
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
IL221742A (en) Oral Pharmaceuticals Containing Debigtran Etxylate
PT2525789T (pt) Formulações farmacêuticas de naproxeno para encapsulação de gel mole e combinações das mesmas
GB2486567B (en) Pharmaceutical formulation
HK1183228A1 (zh) 口服藥物治療方法和組合物
PL2557943T3 (pl) Doustne weterynaryjne kompozycje farmaceutyczne i nutraceutyki
HUE053412T2 (hu) Loratadin gyógyászati kiszerelései kapszulába záráshoz, és ezek kombinációi
HRP20141240T1 (en) An inhalable pharmaceutical composition
HK1182093A1 (zh) 生物鹼氨基酯衍生物及其藥物組合物
IL224191A (en) Compositions of vitamin d and cmc epi-14 analogues
EP2597084A4 (en) N-HYDROXYFORMAMID DERIVATIVE AND MEDICAMENT THEREFOR
IL221501A (en) Medicinal product containing miramistine
EP2419085A4 (en) IMPROVED DEVICES FOR ORAL MEDICINAL PRODUCTS AND MEDICINAL PRODUCTS
EP2780029A4 (en) ORAL LEPTIN FORMULATIONS AND USES THEREOF
PT2568970T (pt) Formulações farmacêuticas estáveis contendo um anti-histamínico
EP2404588A4 (en) PACKAGING FOR SOLID PHARMACEUTICAL PREPARATION
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION
GB201012047D0 (en) Pharmaceutical formulations
GB201012046D0 (en) Pharmaceutical formulations
GB201002451D0 (en) Pharmaceutical comopitions and devices